Selected Antineoplastic Systemic Enzyme Inhibitors/Strong 3A4 Inhibitors
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may slow down how quickly your liver processes your cancer medicine.
What might happen:
The amount of your cancer medicine in your blood may increase and cause more side effects than normal.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to adjust the dose of your cancer medicine while your are taking the other medicine. Let your doctor know if you have an increase in diarrhea, nausea, stomach upset, or vomiting; if you have any unusual bleeding; if you have any chest pain or pressure, numbness or weakness on one side or your body, trouble talking, or severe headache; if you have any swelling, weight gain, or shortness of breath; have a fever; develop an increased thirst, urinate more often than normal, or if your breath smells like fruit; develop eye pain/swelling/redness or blurred vision or other vision changes; or if you notice an irregular heartbeat or have dizziness or fainting episodes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Inlyta (axitinib) US prescribing information. Pfizer Inc. January, 2012.
2.Cometriq (cabozantinib) US prescribing information. Exelixix, Inc. November 29, 2012.
3.Xalkori (crizotinib) US prescribing information. Pfizer Inc. November, 2013.
4.Tafinlar (dabrafenib) US prescribing information. GlaxoSmithKline May, 2013.
5.Sprycel (dasatinib) US prescribing information. Bristol-Myers Squibb Company June, 2013.
6.Imbruvica (ibrutinib) US prescribing information. Janssen Biotech, Inc. November, 2013.
7.Tykerb (lapatinib) US prescribing information. GlaxoSmithKline October, 2013.
8.Tasigna (nilotinib) US prescribing information. Novartis Pharmaceuticals Corporation June, 2013.
9.Votrient (pazopanib) US prescribing information. GlaxoSmithKline November, 2013.
10.Sutent (sunitinib malate) US prescribing information. Pfizer Inc. August, 2013.
11.Iclusig (ponatinib) US prescribing information. ARIAD Pharmaceuticals Inc. December, 2013.
12.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
13.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ DrugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
14.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.